Share on LinkedInShare on LinkedIn

ARTICLE · 02 DECEMBER 2015

Life Sciences M&A Sees New Heights In 2015

2015 continues to see record-setting activity in both the frequency and value of M&A deals involving pharmaceutical companies, and generally in the life-sciences sector.

CanadaCorporate/Commercial Law

2015 continues to see record-setting activity in both the frequency and value of M&A deals involving pharmaceutical companies, and generally in the life-sciences sector. According to a report published by PricewaterhouseCoopers, the combined value of closed M&A deals in the life-sciences and pharmaceutical sector surpassed USD $320Bn in the first three quarters of 2015. Further, a recently announced inversion deal between two major players in the pharmaceutical space has been valued at USD $155Bn. If successful, this will be the largest inversion deal in any sector, and the largest M&A deal in the history of the life-sciences sector.

Against this backdrop, Biopharm Insight and Mergermarket recently issued a report entitled "Life lines: Life-sciences M&A and the rise of personalised medicine."

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from